Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 1/2009

01-01-2009 | Adis Drug Profile

Ropinirole Prolonged Release

In Advanced Parkinson’s Disease

Authors: Juliane Weber, Gillian M. Keating

Published in: CNS Drugs | Issue 1/2009

Login to get access

Abstract

▴ Ropinirole prolonged release is a non-ergoline dopamine receptor agonist that is indicated for the treatment of Parkinson’s disease.
▴ Once-daily ropinirole prolonged release and threetimes-daily ropinirole immediate release have similar exposure over 24 hours. The prolonged-release formulation is associated with fewer fluctuations in plasma ropinirole concentrations.
▴ Two well designed, placebo- or active comparatorcontrolled trials examined the efficacy of ropinirole prolonged release in patients with advanced Parkinson’s disease suboptimally controlled by levodopa. In the placebo-controlled trial, 24 weeks’ therapy with ropinirole prolonged release 6–24 mg once daily reduced hours of ‘off’ time (primary endpoint) to a significantly greater extent than placebo. In the active comparator-controlled trial, significantly more ropinirole prolonged-release recipients than ropinirole immediate-release recipients maintained a ≥20% reduction from baseline in ‘off’ time at week 24 (primary endpoint).
▴ Ropinirole prolonged release 6–24 mg once daily was generally well tolerated in patients with advanced Parkinson’s disease; adverse events were generally typical of non-ergoline dopamine receptor agonists.
Footnotes
1
Registered as Requip-Modutab®, ReQuip® LP, ReQuip® XL™, ReQuip® Depot and ReQuip® Prolib.
 
Literature
1.
2.
Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001 Jun; 56(11 Suppl. 5): S1–88CrossRef
3.
Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet 2004 May 29; 363: 1783–93CrossRef
4.
Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 Apr 11; 66(7): 983–95CrossRef
5.
National Collaborating Centre for Chronic Conditions. Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2006
6.
Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007 Apr 3; 68(14): 1108–15CrossRef
7.
Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson’s disease. Clin Ther 2007 Dec; 29(12): 2654–66CrossRef
8.
Tompson D, Oliver-Willwong, R. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson’s disease. Clin Neuropharmacol. Epub 2008 Oct 23
9.
10.
GlaxoSmithKline. Ropinirole 2, 3, 4 and 8 mg prolongedrelease tablets: EU mutual recognition summary of product characteristics. GlaxoSmithKline, 2007 Nov 27
11.
12.
Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson’s disease. Drugs 2000 Jul; 60(1): 115–37CrossRef
13.
Jost WH, Angersbach D. Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev 2005; 11(3): 253–72CrossRef
14.
Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000 Oct; 39(4): 243–54CrossRef
15.
Stocchi F, Stover NP, Giorgi L. Ropinirole 24-hour prolonged release as adjunct to L-dopa in patients with advanced Parkinson’s disease: efficacy according to baseline depression score [abstract no. 295]. Mov Disord 2007; 22Suppl. 16: S90
16.
Hersh BP, Stover NP, Elmer LW, et al. Early efficacy of adjunctive ropinirole 24-hour in patients with advanced PD [abstract no. M-78]. Ann Neurol 2007; 62Suppl. 11: S35
17.
Isaacson S, Pahwa R, Earl N. Ropinirole 24-hour prolongedrelease adjunctive therapy improves cardinal symptoms in patients with advanced Parkinson’s disease not optimally controlled with L-dopa [abstract no. 2.238]. Parkinsonism Relat Disord 2007; 13Suppl. 2: S108
18.
Sethi KD, Stocchi F, Giorgi L. Ropinirole 24-hour prolonged release in advanced Parkinson’s disease: relationship between treatment response and disease severity [abstract no. 301]. Mov Disord 2007; 22Suppl. 16: S92–3
19.
Stocchi F, Hunter B, Giorgi L, et al. An evaluation of symptom control in patients with advanced PD receiving adjunctive ropinirole 24-hour prolonged release versus ropinirole immediate release: results from the PREPARED study [abstract]. 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23–26; Madrid
20.
Stocchi F, Hunter B, Giorgi L, et al. Adjunctive ropinirole 24-hour prolonged release compared with ropinirole immediate release in patients with advanced Parkinson’s disease (PD): the PREPARED study [abstract]. 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23–26; Madrid
21.
Schapira AHV, Stocchi F, Hunter B, et al. Adjunctive ropinirole 24-hour prolonged release compared with adjunctive ropinirole immediate release in patients with advanced PD: results from a per-protocol analysis of the PREPARED study [abstract]. 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23–26; Madrid
22.
Watts RL, Sethi KD, Pahwa R, et al. Ropinirole 24-hour prolonged release delays the onset of dyskinesia compared with carbidopa/levodopa in patients with Parkinson’s disease treated with levodopa [abstract no. PI 138]. Eur J Neurol 2007; 14Suppl. 1: 65
23.
Metadata
Title
Ropinirole Prolonged Release
In Advanced Parkinson’s Disease
Authors
Juliane Weber
Gillian M. Keating
Publication date
01-01-2009
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 1/2009
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/0023210-200923010-00006

Other articles of this Issue 1/2009

CNS Drugs 1/2009 Go to the issue

Therapy in Practice

Psychopharmacological Treatment of Oppositional Defiant Disorder

Review Article

Getting into the Brain

Review Article

Withdrawing Benzodiazepines in Primary Care

Original Research Article

Effectiveness of Lithium in Children and Adolescents with Conduct Disorder

Adis Drug Profile

Eslicarbazepine Acetate